Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $22.1 million.

  • Lyra Therapeutics' Cash & Equivalents fell 1431.45% to $22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.1 million, marking a year-over-year decrease of 1431.45%. This contributed to the annual value of $40.6 million for FY2024, which is 7088.65% up from last year.
  • According to the latest figures from Q3 2025, Lyra Therapeutics' Cash & Equivalents is $22.1 million, which was down 1431.45% from $29.8 million recorded in Q2 2025.
  • Lyra Therapeutics' Cash & Equivalents' 5-year high stood at $122.1 million during Q2 2022, with a 5-year trough of $17.8 million in Q1 2024.
  • Over the past 5 years, Lyra Therapeutics' median Cash & Equivalents value was $33.9 million (recorded in 2022), while the average stood at $45.9 million.
  • Per our database at Business Quant, Lyra Therapeutics' Cash & Equivalents surged by 9090.67% in 2022 and then tumbled by 7635.34% in 2023.
  • Lyra Therapeutics' Cash & Equivalents (Quarter) stood at $46.1 million in 2021, then decreased by 26.33% to $33.9 million in 2022, then tumbled by 30.04% to $23.7 million in 2023, then skyrocketed by 70.89% to $40.6 million in 2024, then crashed by 45.54% to $22.1 million in 2025.
  • Its Cash & Equivalents stands at $22.1 million for Q3 2025, versus $29.8 million for Q2 2025 and $31.7 million for Q1 2025.